Vista Pharmaceuticals Ltd
Incorporated in 1992, Vista Pharmaceuticals
Ltd manufactures and sells pharmaceutical, medical and veterinary preparations[1]
- Market Cap ₹ 38.4 Cr.
- Current Price ₹ 6.24
- High / Low ₹ 13.1 / 5.71
- Stock P/E
- Book Value ₹ 7.25
- Dividend Yield 0.00 %
- ROCE -8.53 %
- ROE -10.8 %
- Face Value ₹ 2.00
Pros
- Stock is trading at 0.86 times its book value
Cons
- Company has low interest coverage ratio.
- Promoter holding is low: 21.2%
- Company has a low return on equity of -12.4% over last 3 years.
- Company has high debtors of 505 days.
- Promoter holding has decreased over last 3 years: -14.2%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.30 | 13.75 | 15.38 | 24.18 | 28.92 | 31.07 | 22.76 | 1.27 | 0.39 | 1.00 | 10.12 | 9.79 | 8.63 | |
| 7.08 | 11.05 | 12.78 | 21.12 | 23.59 | 29.84 | 27.56 | 3.00 | 1.66 | 5.32 | 13.41 | 13.81 | 17.08 | |
| Operating Profit | 1.22 | 2.70 | 2.60 | 3.06 | 5.33 | 1.23 | -4.80 | -1.73 | -1.27 | -4.32 | -3.29 | -4.02 | -8.45 |
| OPM % | 14.70% | 19.64% | 16.91% | 12.66% | 18.43% | 3.96% | -21.09% | -136.22% | -325.64% | -432.00% | -32.51% | -41.06% | -97.91% |
| 0.03 | 0.01 | 0.02 | 0.06 | 0.40 | 2.95 | 3.75 | 0.20 | 0.17 | 0.40 | 0.07 | 0.44 | 0.52 | |
| Interest | 0.00 | 0.41 | 0.77 | 0.88 | 1.57 | 1.67 | 1.54 | 1.55 | 0.90 | 1.34 | 1.24 | 0.97 | 0.76 |
| Depreciation | 0.77 | 1.05 | 1.02 | 1.02 | 1.34 | 1.36 | 1.35 | 0.73 | 0.62 | 0.62 | 0.72 | 0.74 | 0.75 |
| Profit before tax | 0.48 | 1.25 | 0.83 | 1.22 | 2.82 | 1.15 | -3.94 | -3.81 | -2.62 | -5.88 | -5.18 | -5.29 | -9.44 |
| Tax % | 2.08% | -8.80% | 8.43% | -1.64% | 22.70% | 18.26% | -6.60% | -47.24% | -66.03% | -3.57% | -12.93% | -12.10% | |
| 0.47 | 1.36 | 0.77 | 1.25 | 2.19 | 0.94 | -3.68 | -2.01 | -0.89 | -5.66 | -4.51 | -4.65 | -7.70 | |
| EPS in Rs | 0.06 | 0.11 | 0.06 | 0.47 | 0.75 | 0.31 | -1.21 | -0.55 | -0.24 | -1.54 | -1.23 | -1.26 | -1.42 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -3% |
| 5 Years: | -16% |
| 3 Years: | 193% |
| TTM: | -14% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -6% |
| 3 Years: | % |
| TTM: | -152% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -8% |
| 3 Years: | -11% |
| 1 Year: | -50% |
| Return on Equity | |
|---|---|
| 10 Years: | -5% |
| 5 Years: | -10% |
| 3 Years: | -12% |
| Last Year: | -11% |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 15.00 | 5.00 | 5.00 | 5.31 | 5.83 | 6.07 | 6.07 | 7.36 | 7.36 | 7.51 | 9.43 | 12.31 | 12.31 |
| Reserves | -5.91 | 5.44 | 6.21 | 11.29 | 26.03 | 29.73 | 23.57 | 25.49 | 28.09 | 29.20 | 31.03 | 33.11 | 32.33 |
| 0.00 | 4.04 | 7.88 | 11.33 | 11.06 | 11.17 | 15.47 | 10.71 | 12.55 | 9.96 | 7.96 | 7.40 | 8.50 | |
| 4.97 | 8.30 | 7.29 | 13.69 | 10.08 | 5.79 | 6.01 | 9.05 | 7.59 | 9.36 | 9.56 | 7.47 | 7.82 | |
| Total Liabilities | 14.06 | 22.78 | 26.38 | 41.62 | 53.00 | 52.76 | 51.12 | 52.61 | 55.59 | 56.03 | 57.98 | 60.29 | 60.96 |
| 11.69 | 10.73 | 9.96 | 13.46 | 17.67 | 20.52 | 20.66 | 19.93 | 19.33 | 19.74 | 19.32 | 18.70 | 18.64 | |
| CWIP | 0.00 | 0.00 | 0.00 | 1.99 | 7.11 | 8.54 | 8.78 | 9.08 | 9.08 | 9.33 | 9.82 | 10.14 | 10.55 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.03 | 0.02 | 0.04 | 0.03 | 0.02 | 0.02 | 0.05 | 0.07 |
| 2.37 | 12.05 | 16.42 | 26.17 | 28.20 | 23.67 | 21.66 | 23.56 | 27.15 | 26.94 | 28.82 | 31.40 | 31.70 | |
| Total Assets | 14.06 | 22.78 | 26.38 | 41.62 | 53.00 | 52.76 | 51.12 | 52.61 | 55.59 | 56.03 | 57.98 | 60.29 | 60.96 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.09 | -3.53 | -2.50 | 2.57 | -4.58 | 3.30 | 0.80 | -6.75 | -0.99 | -1.71 | -4.91 | -6.98 | |
| 0.01 | -0.09 | -0.24 | -3.61 | -10.61 | -5.65 | -1.73 | -0.30 | -0.01 | -1.27 | -0.79 | -0.44 | |
| 0.00 | 3.63 | 3.07 | 6.36 | 11.22 | 1.43 | 0.28 | 6.96 | 0.94 | 3.11 | 5.59 | 8.06 | |
| Net Cash Flow | -0.08 | 0.00 | 0.34 | 5.32 | -3.98 | -0.92 | -0.64 | -0.09 | -0.07 | 0.13 | -0.11 | 0.64 |
| Free Cash Flow | -0.10 | -3.63 | -2.75 | -1.07 | -15.24 | -2.35 | -0.93 | -7.05 | -1.00 | -2.98 | -5.70 | -7.42 |
| CFO/OP | -7% | -131% | -89% | 84% | -86% | 299% | -17% | 390% | 78% | 64% | 149% | 163% |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 45.30 | 299.70 | 231.15 | 136.01 | 137.06 | 98.09 | 164.86 | 623.66 | 9,789.49 | 4,106.25 | 515.04 | 504.81 |
| Inventory Days | 51.61 | 10.20 | 96.66 | 184.54 | 249.51 | 161.60 | 147.59 | 4,840.00 | 9,203.92 | 990.53 | 278.78 | 359.32 |
| Days Payable | 323.11 | 359.43 | 236.24 | 293.13 | 208.80 | 75.56 | 78.67 | 2,555.00 | 5,297.43 | 1,007.30 | 304.24 | 244.35 |
| Cash Conversion Cycle | -226.21 | -49.53 | 91.57 | 27.41 | 177.77 | 184.14 | 233.77 | 2,908.66 | 13,695.97 | 4,089.48 | 489.58 | 619.78 |
| Working Capital Days | -110.38 | -8.49 | 205.76 | 12.23 | 136.94 | 136.51 | 80.83 | 1,681.30 | 10,154.49 | 3,460.20 | 317.75 | 440.31 |
| ROCE % | 5.42% | 14.09% | 9.53% | 8.93% | 12.39% | 6.27% | -5.21% | -5.10% | -3.76% | -9.59% | -7.74% | -8.53% |
Insights
In beta| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Export Sales Revenue INR Lakhs |
|
|||||||||||
| Electricity Consumption KWH |
||||||||||||
| Number of Permanent Employees Count |
||||||||||||
| Net Capital Turnover Ratio Times |
||||||||||||
Documents
Announcements
-
Closure of Trading Window
27 Mar - Vista Pharmaceuticals: trading window closed from 1 April 2026 until 48 hours after audited results for year/quarter ending 31.03.2026.
-
Board Meeting Outcome for Un Audited Financial Results For The Quarter Ended 31.12.2025
13 Feb - Unaudited Q3/9M results to 31.12.2025: ₹20,543 lakh ECL provision; ₹30,750 lakh warrant upfront; net loss reported.
-
Results For The Quarter Ended 31.12.2025
13 Feb - Unaudited Q3/9M results: loss; ₹20,543 lakh ECL; ₹30,750 lakh warrant advance received.
-
Update on board meeting
5 Feb - Board meeting on 13 Feb 2026 to consider unaudited results and limited review for quarter/nine months ended 31.12.2025.
-
Board Meeting Intimation for 1. Unaudited Financial Results For The Quarter And Nine Months Ended 31.12.2025.
2. Limited Review Report Quarter And Nine Months 31.12.2025.
3. Any Other Business With The Permission Of The Chair.
5 Feb - Board meeting on 13-Feb-2026 to approve Q3/9M unaudited results and limited review for 31-12-2025.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1][2]
a) The company offers over the counter & prescription generic drug products consisting of tablets, capsules and liquids covering various therapeutic categories and veterinary preparations
b) It manufactures pharmaceutical drugs such as sulphamethoxazole, trimethoprim
and isoxsuprime.
c) The company also sells its products to related companies (Common Directors) engaged in manufacturing formulations